blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2971035

EP2971035 - RECOMBINANT POLYPEPTIDE PRODUCTION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  17.04.2020
Database last updated on 05.10.2024
FormerThe patent has been granted
Status updated on  10.05.2019
FormerGrant of patent is intended
Status updated on  28.02.2019
FormerExamination is in progress
Status updated on  26.05.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
MedImmune, LLC
One MedImmune Way
Gaithersburg, MD 20878 / US
[2016/03]
Inventor(s)01 / STREICHER, Katie
c/o Medlmmune LLC
One Medlmmune Way
Gaithersburg, MD 20878 / US
02 / JACOBS, Jonathan
c/o Medlmmune LLC
One Medlmmune Way
Gaithersburg, MD 20878 / US
03 / GEORGANTAS III, Robert, W.
c/o Medlmmune LLC
One Medlmmune Way
Gaithersburg, MD 20878 / US
04 / GREENLEES, Lydia
c/o Medlmmune LLC
One Medlmmune Way
Gaithersburg, MD 20878 / US
05 / RANADE, Koustubh
c/o Medlmmune LLC
One Medlmmune Way
Gaithersburg, MD 20878 / US
06 / BOWEN, Michael
c/o Medlmmune LLC
One Medlmmune Way
Gaithersburg, MD 20878 / US
 [2016/03]
Representative(s)AstraZeneca Intellectual Property
Eastbrook House
Shaftesbury Road
Cambridge CB2 8BF / GB
[N/P]
Former [2019/24]AstraZeneca
Milstein Building
Granta Park
Cambridge CB21 6GH / GB
Former [2016/03]Ttofi, Evangelia
MedImmune Limited
Milstein Building
Granta Park
Cambridge
Cambridgeshire CB21 6GH / GB
Application number, filing date14776495.512.03.2014
[2016/03]
WO2014US24512
Priority number, dateUS201361782180P14.03.2013         Original published format: US 201361782180 P
[2016/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014159633
Date:02.10.2014
Language:EN
[2014/40]
Type: A1 Application with search report 
No.:EP2971035
Date:20.01.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 02.10.2014 takes the place of the publication of the European patent application.
[2016/03]
Type: B1 Patent specification 
No.:EP2971035
Date:12.06.2019
Language:EN
[2019/24]
Search report(s)International search report - published on:US02.10.2014
(Supplementary) European search report - dispatched on:EP12.10.2016
ClassificationIPC:C12N15/113, C12N15/67, C12N15/85, C12N5/16, C12P21/02
[2016/45]
CPC:
C12N15/113 (EP,US); C07K14/705 (US); C07K16/00 (EP,US);
C07K16/4208 (US); C12N9/00 (US); C12P21/02 (EP,US);
C07K2317/14 (EP,US); C07K2317/21 (US); C07K2317/22 (US);
C07K2317/24 (US); C07K2317/31 (US); C07K2317/40 (US);
C07K2317/565 (US); C07K2317/622 (US); C12N2310/113 (EP,US);
C12N2330/50 (EP,US); C12N2501/65 (EP,US); C12N2799/027 (EP,US);
C12Q2600/178 (EP,US) (-)
Former IPC [2016/03]C12P19/34, C12P21/06, C12N5/07, C12N5/16
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/03]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:HERSTELLUNG VON REKOMBINANTEN POLYPEPTIDEN[2016/03]
English:RECOMBINANT POLYPEPTIDE PRODUCTION[2016/03]
French:PRODUCTION DE POLYPEPTIDE RECOMBINÉ[2016/03]
Entry into regional phase13.10.2015National basic fee paid 
13.10.2015Search fee paid 
13.10.2015Designation fee(s) paid 
13.10.2015Examination fee paid 
Examination procedure13.10.2015Examination requested  [2016/03]
28.04.2017Amendment by applicant (claims and/or description)
29.05.2017Despatch of a communication from the examining division (Time limit: M04)
03.10.2017Reply to a communication from the examining division
28.11.2017Despatch of a communication from the examining division (Time limit: M06)
24.05.2018Reply to a communication from the examining division
09.10.2018Despatch of a communication from the examining division (Time limit: M04)
01.02.2019Reply to a communication from the examining division
01.03.2019Communication of intention to grant the patent
30.04.2019Fee for grant paid
30.04.2019Fee for publishing/printing paid
30.04.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  29.05.2017
Opposition(s)13.03.2020No opposition filed within time limit [2020/21]
Fees paidRenewal fee
31.03.2016Renewal fee patent year 03
10.03.2017Renewal fee patent year 04
13.03.2018Renewal fee patent year 05
01.04.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU12.03.2014
AL12.06.2019
AT12.06.2019
CY12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
MC12.06.2019
MK12.06.2019
MT12.06.2019
PL12.06.2019
RO12.06.2019
RS12.06.2019
SI12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
IE12.03.2020
LU12.03.2020
[2022/32]
Former [2022/28]HU12.03.2014
AL12.06.2019
AT12.06.2019
CY12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
MC12.06.2019
MT12.06.2019
PL12.06.2019
RO12.06.2019
RS12.06.2019
SI12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
IE12.03.2020
LU12.03.2020
Former [2021/08]AL12.06.2019
AT12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
MC12.06.2019
PL12.06.2019
RO12.06.2019
RS12.06.2019
SI12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
IE12.03.2020
LU12.03.2020
Former [2021/04]AL12.06.2019
AT12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
MC12.06.2019
PL12.06.2019
RO12.06.2019
RS12.06.2019
SI12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
LU12.03.2020
Former [2020/50]AL12.06.2019
AT12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
MC12.06.2019
PL12.06.2019
RO12.06.2019
RS12.06.2019
SI12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
Former [2020/36]AL12.06.2019
AT12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
PL12.06.2019
RO12.06.2019
RS12.06.2019
SI12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
Former [2020/24]AL12.06.2019
AT12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
PL12.06.2019
RO12.06.2019
RS12.06.2019
SI12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
PT14.10.2019
IS24.02.2020
Former [2020/22]AL12.06.2019
AT12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
RO12.06.2019
RS12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
Former [2020/17]AL12.06.2019
AT12.06.2019
CZ12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
RO12.06.2019
RS12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
Former [2020/14]AL12.06.2019
AT12.06.2019
CZ12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
RO12.06.2019
RS12.06.2019
SK12.06.2019
SM12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
Former [2020/12]AL12.06.2019
AT12.06.2019
CZ12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
RO12.06.2019
RS12.06.2019
SK12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
Former [2020/11]AL12.06.2019
AT12.06.2019
CZ12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
RO12.06.2019
RS12.06.2019
SK12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
PT14.10.2019
Former [2020/10]AL12.06.2019
AT12.06.2019
CZ12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
RO12.06.2019
RS12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
PT14.10.2019
Former [2020/09]AL12.06.2019
CZ12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
RS12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
Former [2019/51]AL12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
RS12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
Former [2019/50]AL12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
RS12.06.2019
NO12.09.2019
GR13.09.2019
Former [2019/47]FI12.06.2019
LT12.06.2019
NO12.09.2019
Documents cited:Search[Y]WO2008015662  (UNIV DUBLIN CITY [IE], et al) [Y] 1-17 * claim 1; table 1 *;
 [I]  - Noëlia Sanchez, "miRNAs as tools to improve CHO cell bioprocess phenotypes", Ph. D. thesis, Dublin, Ireland, (201301), pages i-xi,1 - 474, URL: http://doras.dcu.ie/17716/1/Final_bound_thesis_NSanchez.pdf, (20160919), XP055303658 [I] 1-17 * page 111 - page 128 * * page 337 - page 338 *
 [Y]  - ALIAKSANDR DRUZ ET AL, "Stable inhibition of mmu-miR-466h-5p improves apoptosis resistance and protein production in CHO cells", METABOLIC ENGINEERING, US, (20130129), vol. 16, doi:10.1016/j.ymben.2012.12.004, ISSN 1096-7176, pages 87 - 94, XP055303725 [Y] 1-17 * figures 2,6 *

DOI:   http://dx.doi.org/10.1016/j.ymben.2012.12.004
 [Y]  - MULLER D ET AL, "MicroRNAs as targets for engineering of CHO cell factories", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 26, no. 7, doi:10.1016/J.TIBTECH.2008.03.010, ISSN 0167-7799, (20080528), pages 359 - 365, (20080528), XP022757292 [Y] 1-17 * table 1 *

DOI:   http://dx.doi.org/10.1016/j.tibtech.2008.03.010
 [X]  - WING PUI TSANG ET AL, "Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3", APOPTOSIS ; AN INTERNATIONAL JOURNAL ON PROGRAMMED CELL DEATH, KLUWER ACADEMIC PUBLISHERS, BO, (20080829), vol. 13, no. 10, ISSN 1573-675X, pages 1215 - 1222, XP019599278 [X] 17 * page 1216; figures 2,4 *
 [X]  - ROBERTSON BARBARA ET AL, "Specificity and functionality of microRNA inhibitors", SILENCE, BIOMED CENTRAL LTD, LONDON, UK, (20100401), vol. 1, no. 1, doi:10.1186/1758-907X-1-10, ISSN 1758-907X, page 10, XP021084868 [X] 17 * figure 1 *

DOI:   http://dx.doi.org/10.1186/1758-907X-1-10
 [A]  - ROUSH S ET AL, "The let-7 family of microRNAs", TRENDS IN CELL BIOLOGY, ELSEVIER SCIENCE LTD, XX, vol. 18, no. 10, doi:10.1016/J.TCB.2008.07.007, ISSN 0962-8924, (20080904), pages 505 - 516, (20080904), XP025468977 [A] 1-17 * figure 2 *

DOI:   http://dx.doi.org/10.1016/j.tcb.2008.07.007
 [Y]  - NIALL BARRON ET AL, "MicroRNAs: tiny targets for engineering CHO cell phenotypes?", BIOTECHNOLOGY LETTERS, SPRINGER NETHERLANDS, DORDRECHT, (20100925), vol. 33, no. 1, doi:10.1007/S10529-010-0415-5, ISSN 1573-6776, pages 11 - 21, XP019869481 [Y] 1-17 * table 2 *

DOI:   http://dx.doi.org/10.1007/s10529-010-0415-5
 [A]  - JUAN A. HERNÁNDEZ BORT ET AL, "Dynamic mRNA and miRNA profiling of CHO-K1 suspension cell cultures", BIOTECHNOLOGY JOURNAL, (20110805), vol. 7, no. 4, doi:10.1002/biot.201100143, ISSN 1860-6768, pages 500 - 515, XP055094799 [A] 1-17 * figure 5 *

DOI:   http://dx.doi.org/10.1002/biot.201100143
 [A]  - VAIBHAV JADHAV ET AL, "A screening method to assess biological effects of microRNA overexpression in Chinese hamster ovary cells", BIOTECHNOLOGY AND BIOENGINEERING, (20120322), vol. 109, no. 6, doi:10.1002/bit.24490, ISSN 0006-3592, pages 1376 - 1385, XP055094798 [A] 1-17 * figures 3,4 *

DOI:   http://dx.doi.org/10.1002/bit.24490
 [YP]  - VAIBHAV JADHAV ET AL, "CHO microRNA engineering is growing up: Recent successes and future challenges", BIOTECHNOLOGY ADVANCES, (20130802), vol. 31, no. 8, doi:10.1016/j.biotechadv.2013.07.007, ISSN 0734-9750, pages 1501 - 1513, XP055094976 [YP] 1-17 * table 1 *

DOI:   http://dx.doi.org/10.1016/j.biotechadv.2013.07.007
 [T]  - LYDIA GREENLEES ET AL, "Inhibition of microRNA-let-7a Increases the Specific Productivity of Antibody-Producing CHO Cell Lines", GENOMICS AND APPLIED BIOLOGY, (20140726), vol. 5, no. 1, doi:10.5376/gab.2014.05.0001, pages 1 - 15, XP055303694 [T] 1-17 * the whole document *

DOI:   http://dx.doi.org/10.5376/gab.2014.05.0001
International search[Y]US2009035862  (CALOS MICHELE P [US]);
 [Y]US2010190256  (RAWSON NANCY ELLEN [US], et al);
 [Y]US2010226884  (CHANG CHIEN-HSING [US], et al);
 [Y]US2010267573  (KEENE JACK D [US], et al);
 [X]WO2010129919  (RES DEV FOUNDATION [US], et al);
 [Y]US2011098346  (WANG SHU [SG], et al);
 [Y]US2011189137  (RANA TARIQ M [US]);
 [Y]US2011224286  (YU XIJIE [US], et al);
 [Y]US2012230959  (ABBOT STEWART [US], et al);
 [A]  - KHODAYARI, N. ET AL., "EphrinA1 inhibits Malignant Mesothelioma Tumor Growth Via let-7 microRNA-Mediated Repression Of The RAS Oncogene .", CANCER GENE THERAPY., (20110826), vol. 18, pages 806 - 816, XP055279296

DOI:   http://dx.doi.org/10.1038/cgt.2011.50
Examination   - KIRANMAI GUMIREDDY ET AL, "Small-Molecule Inhibitors of MicroRNA miR-21 Function", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, (20080915), vol. 47, no. 39, doi:10.1002/anie.200801555, ISSN 1433-7851, pages 7482 - 7484, XP055198586

DOI:   http://dx.doi.org/10.1002/anie.200801555
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.